UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000010905
Receipt number R000012761
Scientific Title Randomized crossover clinical trial comparing the effects of alogliptin and linagliptin on glycemic metabolism in hemodialysis patients with type 2 diabetes mellitus
Date of disclosure of the study information 2013/06/10
Last modified on 2014/01/25 18:49:26

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Randomized crossover clinical trial comparing the effects of alogliptin and linagliptin on glycemic metabolism in hemodialysis patients with type 2 diabetes mellitus

Acronym

Comparison of alogliptin and linagliptin in hemodialysis patients with type 2 diabetes mellitus

Scientific Title

Randomized crossover clinical trial comparing the effects of alogliptin and linagliptin on glycemic metabolism in hemodialysis patients with type 2 diabetes mellitus

Scientific Title:Acronym

Comparison of alogliptin and linagliptin in hemodialysis patients with type 2 diabetes mellitus

Region

Japan


Condition

Condition

hemodialysis patients with type 2 diabetes mellitus

Classification by specialty

Endocrinology and Metabolism Nephrology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To compare the effects of alogliptin and linagliptin on glycemic control and safety by crossover method

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

glycoalbumin and Hemoglobin A1c

Key secondary outcomes

plasma glucose, C-peptide, LDL cholesterol, adverse event


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation

NO

Institution consideration


Blocking


Concealment

Numbered container method


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Administration of alogliptin 6.25mg in the first 3 months followed by the administration of linagliptin 5mg for 3 months

Interventions/Control_2

Administration of linagliptin 5mg in the first 3 months followed by the administration of alogliptin 6.25mg for 3 months

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Hemodialysis patients of type 2 diabetes mellitus treated with DPP-4 inhibitors

Key exclusion criteria

1)Patients who has a history of hypersensitivity
2)Pregnant or possibly pregnant women and women on lactation
3)Ineligible patients according to the investigator's judgment
4)The patients who do not agree with this study

Target sample size

20


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Ogawa Tetsuya

Organization

Tokyo Women's Medical University Medical Center East

Division name

Internal medicine

Zip code


Address

2-1-10 Nishiogu, Arakawa-ku, Tokyo, 116-8567, Japan

TEL

03-3810-1111

Email



Public contact

Name of contact person

1st name
Middle name
Last name Yamashita Tetsuri

Organization

Minamisenju hospital

Division name

Dialysis internal medicine

Zip code


Address

5-10-1 Minamisenju, Arakawa-ku, Tokyo 116-0003, Japan

TEL

03-3806-2232

Homepage URL


Email

tetsuri218@yahoo.co.jp


Sponsor or person

Institute

Minamisenju hospital

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

南千住病院(東京都)


Other administrative information

Date of disclosure of the study information

2013 Year 06 Month 10 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2013 Year 06 Month 05 Day

Date of IRB


Anticipated trial start date

2013 Year 06 Month 10 Day

Last follow-up date

2014 Year 01 Month 25 Day

Date of closure to data entry

2014 Year 01 Month 25 Day

Date trial data considered complete

2014 Year 01 Month 25 Day

Date analysis concluded

2014 Year 01 Month 25 Day


Other

Other related information



Management information

Registered date

2013 Year 06 Month 08 Day

Last modified on

2014 Year 01 Month 25 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012761


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name